NEW YORK (GenomeWeb) – Enzo Biochem reported today that its fiscal third quarter revenues climbed 10 percent over last year on a strong performance for its clinical lab and life science divisions.

For the three-month period ended April 30, the company reported total revenues of $26.4 million compared to $24 million in the same period a year earlier. Clinical lab services revenues grew 16 percent to $18.2 million from $15.7 million, while life sciences revenues edged up to $8 million from $7.9 million. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.